1315 Capital related stories
All articles and analysis
Encore Dermatology secures $20 mln from HorizonHorizon has provided a $20 million venture loan facility to Encore Dermatology. Headquartered in Malvern, Pennsylvania, Encore Dermatology is a specialty dermatology company. Encore is backed by EW Healthcare Partners, 1315 Capital and Longitude Capital.
- 1315 Capital raises $300 mln for second fund
Philadelphia-based 1315 Capital has raised $300 million for its fund, 1315 Capital II, according to a regulatory filing https://www.sec.gov/Archives/edgar/data/1730825/000173082518000001/xslFormDX01/primary_doc.xml The firm invests in pharmaceutical, medical technology, and healthcare service companies, according to its website http://www.1315capital.com/ It is led by Adele Oliva, Michael Koby, and Brian Schwenk. The fund closed at its hard cap of $300 million, exceeding its $250 million target, according to a press release https://www.prnewswire.com/news-releases/1315-capital-completes-single-close-on-over-300-million-healthcare-growth-equity-fund-300596659.html The filing lists 57 investors.
1315 Capital raises $300mThe US-based expansion and growth equity firm closes second fund at hard-cap.
- Reber joins 1315 Capital as partner
Philadelphia-based 1315 Capital, a healthcare-focused growth equity firm, has hired Matthew Q. Reber as a partner. Previously, Reber worked at HealthCare Royalty Partners where he most recently served as a managing director.
- Onkos Surgical lands $17.6 mln Series B
Parsippany, New Jersey-based Onkos Surgical Inc, a specialty medtech company focused on surgical oncology, has raised $17.6 million in Series B funding. Canaan Partners led the round with participation from return backers 1315 Capital and 3D Systems.
- Ampersand and 1315 Capital closes buy of Genoptix
Ampersand Capital Partners and 1315 Capital has completed its previously announced acquisition of Genoptix. The seller was Novartis. No financial terms were disclosed. Based in Carlsbad, California, Genoptix is a hematopathology center.
- Ampersand Capital and 1315 Capital to acquire Genoptix's commercial lab
Ampersand Capital Partners and 1315 Capital have agreed to acquire Genoptix's commercial laboratory. No financial terms were disclosed for the transaction that is being done in partnership with a management group led by Joseph M. Limber. The deal is expected to close in the first quarter of this year. Based in Carlsbad, California, Genoptix is a hematopathology center.